Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 3.387 billion yuan for 2025, representing a year-on-year growth of 13.56%. The net profit attributable to the parent company was 372 million yuan, up 19.20% year-on-year, while the net profit excluding non-recurring items was 298 million yuan, an increase of 8.33% [3][4] - In Q4 2025, the company achieved a revenue of 990 million yuan, marking a year-on-year growth of 34.79%, with a net profit of 111 million yuan, up 86.17% year-on-year [3][4] - The company is accelerating its merger and acquisition strategy to expand overseas channels, with overseas revenue reaching approximately 299 million yuan in 2025, a staggering growth of 405.05% year-on-year [5] - A strategic partnership with Philips has been established, granting the company brand authorization for seven product categories, which is expected to contribute to revenue growth starting in the second half of 2026 [6] Financial Performance Summary - The company expects revenues for 2026, 2027, and 2028 to be 4.132 billion yuan, 5.132 billion yuan, and 6.286 billion yuan, respectively, with growth rates of 22.0%, 24.2%, and 22.5% [8] - The net profit attributable to the parent company is projected to be 466 million yuan, 590 million yuan, and 763 million yuan for 2026, 2027, and 2028, respectively, with growth rates of 25.5%, 26.4%, and 29.3% [8] - The company's gross margin is expected to improve from 53.2% in 2025 to 55.8% in 2028 [10] - The earnings per share (EPS) is forecasted to be 2.23 yuan, 2.82 yuan, and 3.65 yuan for 2026, 2027, and 2028, respectively [10]

可[Ta孚ble医_Sto疗ckN（ameRptType] 301087） 公司点评 2025 年业绩符合预期，增长新动能充足 | 投资评级： | 买入（维持） | | | --- | --- | --- | | 报告日期： | 2026-03-12 |  事件： | | 收盘价（元） | 61.64 | | --- | --- | | 近 12 个月最高/最低（元） | 63.99/29.17 | | 总股本（百万股） | 209 | | 流通股本（百万股） | 194 | | 流通股比例（%） | 92.89 | | 总市值（亿元） | 129 | | 流通市值（亿元） | 120 | 公司价格与沪深 300 走势比较 执业证书号：S0010521120002 邮箱：tangc@hazq.com 执业证书号：S0010523120002 邮箱：lichan@hazq.com 1.【华安医药】公司点评：可孚医疗 场进展迅速 2025-08-28 收入增长持续稳健 2025-05-04 （1）2025Q4 利润端增长喜人。按季度来看，2025Q1-4 分别销售净 利润率为 12.41%/9.90%/10.3 ...

医疗器械 自主创新与外延并购驱动，多元战略布局构筑新增长极 可孚医疗（301087.SZ） 证券研究报告/公司点评报告 2026 年 03 月 10 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2024A | 2025A | 2026E | 2027E | 2028E | | 分析师：祝嘉琦 | | 营业收入（百万元） | 2,983 | 3,387 | 4,200 | 5,285 | 6,266 | | | | 增长率 yoy% | 5% | 14% | 24% | 26% | 19% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 311.75 | 371.61 | 462.51 | 585.35 | 716.47 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | 23% | 19% | 24% | 27% | 22% | | | | 每股收益（元） | 1.49 | 1.78 ...

医疗器械 自主创新与外延并购驱动，多元战略布局构筑新增长极 可孚医疗（301087.SZ） 证券研究报告/公司点评报告 2026 年 03 月 10 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2024A | 2025A | 2026E | 2027E | 2028E | | 分析师：祝嘉琦 | | 营业收入（百万元） | 2,983 | 3,387 | 4,200 | 5,285 | 6,266 | | | | 增长率 yoy% | 5% | 14% | 24% | 26% | 19% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 311.75 | 371.61 | 462.51 | 585.35 | 716.47 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | 23% | 19% | 24% | 27% | 22% | | | | 每股收益（元） | 1.49 | 1.78 ...

Core Insights - The establishment of the Kefu Artificial Intelligence Research Institute marks a significant advancement in Kefu Medical's strategy in the "AI + healthcare" sector, transitioning from isolated applications to a systematic and platform-based approach [1][2] Group 1: Company Developments - Kefu Medical has been deeply involved in the home medical device industry for 20 years, creating a comprehensive product system covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy, serving over 50 million families globally [1] - The company has built three research institutes focusing on medical electronics and rehabilitation medicine, biosensors and innovative materials, and respiratory support, employing nearly 400 R&D personnel and holding approximately 700 authorized patents [1][2] Group 2: AI Research Institute Objectives - The AI Research Institute will focus on key areas such as medical large models and multimodal data analysis, aiming to upgrade products from "functional devices" to "intelligent health management terminals" [2] - The institute plans to implement a flat management model and aims to achieve a full-link closed-loop medical service through the dual drive of "intelligent medical devices" and "AI-driven medical services" [2][3] Group 3: Future Plans and Market Position - The research institute is expected to release the internal large model version 1.0 this year and will first validate AI algorithms on new respiratory devices, transitioning them from "data recorders" to "health analysts" [3] - As AI applications in healthcare deepen, competition is shifting from product performance to algorithm, data accumulation, and systematic R&D capabilities, positioning Kefu Medical for long-term technological evolution and product upgrades [3]